TNFR2 agonist

SOUTH SAN FRANCISCO, Calif., May 7, 2026 TRexBio announced new late-breaking translational and preclinical data supporting TNFR2 agonism as...

SOUTH SAN FRANCISCO, April 29, 2026 TRexBio, Inc. has announced that the first patient has been dosed in the...

SOUTH SAN FRANCISCO, CALIFORNIA | January 27, 2026 — TRexBio, Inc., a clinical-stage biotechnology company focused on precision immunoregulatory...